How Global Biotech Companies Should Adapt Their CTD Dossiers for India

The Common Technical Document (CTD) is the universal language of Pharmaceutical and Biological registration. Most global regulatory agencies, including the USFDA, EMA and PMDA accept the ICH CTD format with regional Module 1 variations. India’s CDSCO also accepts the ICH CTD format for Biological product registrations, but a copy-paste submission of a US or EU dossier will almost certainly fail.

India has a distinct set of regional expectations rooted in its epidemiology, climate zone, patient population and regulatory philosophy that require deliberate localization of the CTD before submission to CDSCO. This article provides a module-by-module guide to adapting CTD dossiers for India.

1. Module 1: Administrative and Regional Information

Module 1 is the most India-specific module and must be entirely rewritten for CDSCO submission. It cannot be reused from US or EU submissions.

1.1 Covering Letter and Application Form

A formal covering letter addressed to the DCGI is required along with the prescribed application form under the NDCT Rules 2019. For new biological drugs, Form CT-04 (clinical trial application) or Form CT-18/21 (marketing authorization) is applicable depending on development stage.

1.2 Indian Labelling

Labelling must comply with the Drugs and Cosmetics Act, 1940 and NDCT Rules, 2019 requirements including the Indian trade name, INN composition, storage conditions, import license number and name and address of the Indian LAA or manufacturer. Promotional claims permitted in the US or EU may not be permissible under Indian standards.

1.3 Prescribing Information

The SmPC or USPI must be adapted to reflect Indian clinical data, Indian patient population characteristics and CDSCO approved indications..

1.4 Risk Management Plan — India Addendum

CDSCO requires an India-specific RMP addendum covering: the PvPI compliance plan, local pharmacovigilance activities, post-marketing surveillance commitments, 15-day expedited SAE reporting and appointment of an India-registered QPPV.

2. Module 2: Summaries and Overviews

Module 2 contains summaries and overviews of other Modules. Include reference of various sub parts like Quality overall summary, Preclinical studies, Clinical summary, etc.be retained from global submissions but must be reviewed for India-specific relevance. Clinical overviews should explicitly address whether Indian patients were included in pivotal trials, justification for clinical waiver if applicable and ethnic sensitivity analysis for the Indian population referencing ICH E5.

3. Module 3: Quality — The Most Intensive Adaptation

3.1 Stability Data — India’s Climate Zone IVb

India falls in ICH Climate Zone IVb — the most demanding stability classification, requiring long-term stability studies at 30°C/75% RH and accelerated studies at 40°C/75% RH. Products stability-tested only under Zone II conditions (25°C/60% RH, relevant for EU/US) require additional Zone IVb data. CDSCO will not accept Zone II data alone for India.

3.2 Indian Reference Standards

Where Indian Pharmacopoeia (IP) standards exist for the Biological substance or related excipients, CDSCO expects compliance with IP standards alongside USP/EP. These must be incorporated into the quality dossier where relevant.

3.3 Container Closure and Packaging

Container closure specifications must reflect Indian packaging requirements — including tamper-evident packaging and compliance with Schedule P and P-1 of the Drugs and Cosmetics Act for shelf-life declarations.

4. Module 4: Non-Clinical Data

Non-clinical data from global programmes is generally acceptable without significant adaptation, provided studies comply with ICH afety guidelines and GLP standards. However, for Biological products with significant immunogenicity concerns (mAbs, biosimilars, cell and gene therapies), CDSCO’s SEC may request additional non-clinical immunogenicity data relevant to Indian populations.

5. Module 5: Clinical Data — Most Critical Localization Requirement

5.1 Ethnic Sensitivity Analysis

The Indian population is genetically distinct from Western and East Asian populations. CDSCO requires an ethnic sensitivity analysis — evaluating whether PK, PD, and efficacy data from global populations can be extrapolated to Indian patients under the ICH E5 framework, including analysis of relevant genetic polymorphisms prevalent in Indian patients.

5.2 Indian Bridging Studies

For most New Biological Drugs, CDSCO requires at least Phase III data from Indian patients. The scale of bridging requirements depends on availability of Indian patients in global trials, disease prevalence differences, ethnic sensitivity concerns, and unmet medical need status in India. A formal waiver request with scientific justification can be submitted if Indian patients were adequately represented in global trials.

5.3 Biosimilar Comparability — Indian Reference Biologic

For biosimilar submissions, the reference biologic must be the Indian-approved reference product — not the EU or US reference. Comparability studies must be conducted against the Indian reference biologic. EU/US comparability data may be submitted as supportive, but the Indian reference remains the primary comparator.

6. Common CTD Localization Failures

Table 1

7. Best Practices

1. Engage an India regulatory expert at the dossier planning stage — not as a final review step.
2. Commission Zone IVb stability studies parallel with global stability programmes.
3. Conduct the ethnic sensitivity analysis using a structured ICH E5-aligned framework.
4. Appoint an India PVOIC and establish PvPI reporting infrastructure before submission.
5. Use the Indian reference biologic for biosimilar comparability from the outset of the development programme.
6. Treat Module 1 as an entirely new document — not a variation of the US/EU version

Conclusion

India CTD localization is a substantive scientific and regulatory exercise that directly determines the approvability of a CDSCO submission. Global biotech companies that invest in India-specific dossier preparation from early in their development programme will experience faster approvals, fewer deficiency queries, and a stronger regulatory relationship with CDSCO.

CliniExperts Services has extensive experience in CTD localization for biological products across biosimilars, monoclonal antibodies, vaccines, and cell and gene therapies. Our regulatory scientists work at the intersection of global ICH standards and Indian CDSCO expectations — ensuring your dossier is not just compliant, but competitive.

Ready to navigate India’s biological regulatory landscape? Contact CliniExperts Services for a complimentary regulatory strategy consultation. Visit www.cliniexperts.com or write to 
contact@cliniexperts.com